A Malaria Vaccine for Control: More Progress.

The article reports on the 45-month follow-up study on the first pediatric efficacy trials to Mozambican children who received the vaccine or control vaccine for malaria. It is mentioned that the vaccine lowered the parasetemia prevalence in the control group, but most importantly, there were no side effects to children on the natural acquisition of immunity to malaria. Furthermore, this research was made since malaria remains a major risk causing 1-2 million deaths annually and a great burden to children and pregnant women in tropical Africa. Lastly, though the next generations of malaria vaccines proves to reduce the disease and associated deaths, there is a need of intensified research and development on antivector methods and effective block on the transmission of the disease.